- List
- By Topic
- On Map
- Search Details

Recruiting, Not yet recruiting, Available Studies | "Liver Cirrhosis, Biliary"
Need help? See RSS Feeds
Choose a feed type:

Recruiting, Not yet recruiting, Available Studies | "Liver Cirrhosis, Biliary" (38 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02937012 | Recruiting | Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders |
|
|
Interventional | Phase 3 |
|
Other |
|
|
34 | All | 18 Years to 65 Years (Adult) | NCT02937012 | 1757 | October 2016 | April 2018 | April 2018 | October 18, 2016 | October 18, 2016 |
|
||
2 | NCT01161953 | Recruiting | Genetic Epidemiology of Primary Biliary Cirrhosis (PBC) |
|
|
Observational |
|
Other |
|
|
1500 | All | 18 Years to 90 Years (Adult, Senior) | NCT01161953 | 670-02 PBC | March 2002 | December 2025 | December 2025 | July 14, 2010 | August 22, 2017 |
|
|||
3 | NCT02823353 | Recruiting | Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis |
|
|
Interventional | Phase 3 |
|
Other |
|
|
200 | All | 18 Years to 70 Years (Adult, Senior) | NCT02823353 | KY20151230-4 | January 2016 | July 2018 | July 2018 | July 6, 2016 | July 7, 2016 |
|
||
4 | NCT03476993 | Not yet recruiting New |
Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
30 | All | 18 Years to 60 Years (Adult) | NCT03476993 | BCD-085-6 | April 2018 | April 2020 | December 2021 | March 26, 2018 | March 26, 2018 |
|
||
5 | NCT03146910 | Recruiting | Swiss Primary Biliary Cholangitis Cohort Study |
|
Observational |
|
Other |
|
|
500 | All | 18 Years and older (Adult, Senior) | NCT03146910 | SASL39 - Swiss PBC Cohort | February 15, 2017 | December 31, 2022 | December 31, 2022 | May 10, 2017 | May 10, 2017 |
|
||||
6 | NCT02308111 | Recruiting | Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis |
|
|
Interventional | Phase 4 |
|
Industry |
|
|
428 | All | 18 Years and older (Adult, Senior) | NCT02308111 | 747-302 | COBALT | December 2014 | December 2024 | April 2025 | December 4, 2014 | March 13, 2018 |
|
|
7 | NCT03468699 | Recruiting | Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia |
|
|
Interventional | Phase 2 |
|
Other |
|
|
20 | All | 1 Year to 15 Years (Child) | NCT03468699 | VinmecRISCGT78 | January 2, 2017 | December 31, 2018 | December 31, 2018 | March 16, 2018 | March 16, 2018 |
|
||
8 | NCT02916290 | Recruiting | Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis |
|
|
Interventional | Phase 3 |
|
Other |
|
|
200 | All | 18 Years to 70 Years (Adult, Senior) | NCT02916290 | KY20151230-6 | January 2016 | December 2018 | September 27, 2016 | September 27, 2016 |
|
|||
9 | NCT02823366 | Recruiting | Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid |
|
|
Interventional | Phase 3 |
|
Other |
|
|
200 | All | 18 Years to 70 Years (Adult, Senior) | NCT02823366 | KY20151230-5 | January 2016 | June 2017 | July 6, 2016 | July 7, 2016 |
|
|||
10 | NCT02193360 | Recruiting | Pilot Study of FFP104 Dose Escalation in PBC Subjects |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
24 | All | 18 Years to 75 Years (Adult, Senior) | NCT02193360 | FFP104-001 2014-001638-27 |
May 2015 | August 2017 | December 2017 | July 17, 2014 | August 24, 2016 |
|
||
11 | NCT03253276 | Recruiting | Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT |
|
|
Interventional | Early Phase 1 |
|
Other |
|
|
8 | All | 18 Years to 85 Years (Adult, Senior) | NCT03253276 | OCAPBC | May 19, 2016 | January 20, 2018 | March 31, 2018 | August 17, 2017 | August 22, 2017 |
|
||
12 | NCT02965911 | Recruiting | Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
72 | All | 18 Years to 65 Years (Adult) | NCT02965911 | BJ302-FGRXGB-002 | January 2016 | January 2019 | January 2019 | November 17, 2016 | November 17, 2016 |
|
||
13 | NCT02916641 | Recruiting | Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid |
|
|
Interventional | Phase 3 |
|
Other |
|
|
200 | All | 18 Years to 70 Years (Adult, Senior) | NCT02916641 | KY20151230-7 | January 2016 | December 2018 | September 27, 2016 | September 27, 2016 |
|
|||
14 | NCT02477462 | Recruiting | Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients |
|
|
Observational |
|
Other |
|
|
200 | All | 18 Years and older (Adult, Senior) | NCT02477462 | 703097 | May 2015 | May 2019 | May 2019 | June 22, 2015 | March 1, 2018 |
|
|||
15 | NCT03489889 | Recruiting New |
Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine |
|
|
Interventional | Not Applicable |
|
Other |
|
|
28 | All | 18 Years and older (Adult, Senior) | NCT03489889 | Gastro FMUSP | December 2016 | December 2017 | June 2018 | April 6, 2018 | April 10, 2018 |
|
||
16 | NCT03301506 | Recruiting | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) |
|
|
Interventional | Phase 2 Phase 3 |
|
Industry |
|
|
356 | All | 18 Years to 75 Years (Adult, Senior) | NCT03301506 | CB8025-31731 | December 12, 2017 | December 2020 | March 2022 | October 4, 2017 | April 5, 2018 |
|
||
17 | NCT03226067 | Recruiting | Study to Assess Safety and Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
102 | All | 18 Years to 80 Years (Adult, Senior) | NCT03226067 | GSN000300 2016-004599-23 |
June 26, 2017 | August 20, 2018 | August 20, 2018 | July 21, 2017 | March 12, 2018 |
|
||
18 | NCT03112681 | Recruiting | A Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
36 | All | 18 Years to 75 Years (Adult, Senior) | NCT03112681 | SARO.16.004.03.PROT | EPICS | August 18, 2017 | January 2019 | March 2019 | April 13, 2017 | April 2, 2018 |
|
|
19 | NCT02955602 | Recruiting | Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
116 | All | 18 Years to 75 Years (Adult, Senior) | NCT02955602 | CB8025-21629 | November 28, 2016 | July 2019 | January 2020 | November 4, 2016 | February 26, 2018 |
|
||
20 | NCT02932449 | Recruiting | A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis |
|
Observational |
|
Industry |
|
|
1500 | All | 18 Years and older (Adult, Senior) | NCT02932449 | TARGET-PBC | October 2016 | September 2021 | September 2021 | October 13, 2016 | April 13, 2018 |
|
||||
21 | NCT02924701 | Recruiting | sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis |
|
|
Observational |
|
Other |
|
|
140 | All | 18 Years and older (Adult, Senior) | NCT02924701 | PBC AU 1 | September 2016 | June 2021 | June 2021 | October 5, 2016 | November 1, 2016 |
|
|||
22 | NCT02931513 | Recruiting | sCD163 in PBC Patients - Assessment of Treatment Response |
|
|
Observational |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Senior) | NCT02931513 | PBC AU 2 | September 2016 | June 2021 | June 2021 | October 13, 2016 | November 1, 2016 |
|
|||
23 | NCT03337074 | Recruiting | Paternally Inherited Phenotypes in Cholestasis |
|
|
Observational |
|
Other |
|
|
200 | All | 16 Years and older (Child, Adult, Senior) | NCT03337074 | 182833 | PIP-C | February 8, 2017 | April 1, 2018 | April 3, 2020 | November 8, 2017 | March 29, 2018 |
|
||
24 | NCT02516605 | Recruiting | A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
163 | All | 18 Years and older (Adult, Senior) | NCT02516605 | CLJN452X2201 2015-001590-41 |
September 9, 2015 | December 10, 2019 | December 10, 2019 | August 6, 2015 | April 19, 2018 |
|
||
25 | NCT02936596 | Recruiting | Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome |
|
|
Interventional | Not Applicable |
|
Other |
|
|
53 | All | 18 Years to 75 Years (Adult, Senior) | NCT02936596 | OS-1 | December 2016 | August 2017 | October 18, 2016 | December 12, 2016 |
|
|||
26 | NCT03394924 | Recruiting | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis |
|
|
Interventional | Phase 2 |
|
Industry / Other |
|
|
119 | All | 18 Years to 75 Years (Adult, Senior) | NCT03394924 | EDP 305-201 | December 27, 2017 | March 2019 | April 2019 | January 9, 2018 | March 21, 2018 |
|
||
27 | NCT03345589 | Not yet recruiting | A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis |
|
|
Interventional | Phase 4 |
|
Other |
|
|
40 | All | 18 Years to 70 Years (Adult, Senior) | NCT03345589 | PBC-3 | January 30, 2018 | December 1, 2018 | January 1, 2019 | November 17, 2017 | January 9, 2018 | |||
28 | NCT03322943 | Recruiting | The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital |
|
Observational |
|
Other |
|
|
300 | All | 25 Years to 85 Years (Adult, Senior) | NCT03322943 | PBC-2 | January 1, 2016 | September 1, 2018 | December 1, 2018 | October 26, 2017 | October 26, 2017 |
|
||||
29 | NCT03188146 | Recruiting | Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid |
|
|
Observational |
|
Other |
|
|
500 | All | 18 Years to 85 Years (Adult, Senior) | NCT03188146 | H&H_PBC_01 | May 1, 2017 | May 1, 2027 | May 1, 2028 | June 15, 2017 | June 15, 2017 |
|
|||
30 | NCT03155932 | Recruiting | Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Patients With Primary Biliary Cholangitis |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
20 | All | 18 Years to 75 Years (Adult, Senior) | NCT03155932 | APD334-010 | December 15, 2017 | December 2018 | December 2018 | May 16, 2017 | April 19, 2018 |
|
||
31 | NCT03124108 | Recruiting | Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
45 | All | 18 Years to 75 Years (Adult, Senior) | NCT03124108 | GFT505B-216-1 2016-003817-80 |
April 5, 2017 | April 2018 | April 2018 | April 21, 2017 | February 21, 2018 |
|
||
32 | NCT03092765 | Recruiting | Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
80 | All | 20 Years to 74 Years (Adult, Senior) | NCT03092765 | E6011/ET1 | March 23, 2017 | February 2020 | March 2020 | March 28, 2017 | October 24, 2017 |
|
||
33 | NCT02943447 | Recruiting | Safety, Tolerability, and Efficacy of GS 9674 in Adults With Primary Biliary Cholangitis Without Cirrhosis |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
75 | All | 18 Years to 70 Years (Adult, Senior) | NCT02943447 | GS-US-427-4024 2016-002443-42 |
PBC-Phase 2 | December 1, 2016 | July 2018 | February 2020 | October 24, 2016 | March 14, 2018 |
|
|
34 | NCT00001971 | Recruiting | Evaluation of Patients With Liver Disease |
|
Observational |
|
NIH | 99999999 | All | 2 Years and older (Child, Adult, Senior) | NCT00001971 | 910214 91-DK-0214 |
September 10, 1991 | January 19, 2000 | April 4, 2018 |
|
||||||||
35 | NCT03265249 | Not yet recruiting | BRIDGE Device for Post-operative Pain Control |
|
|
Interventional | Not Applicable |
|
Other |
|
|
50 | All | 18 Years to 70 Years (Adult, Senior) | NCT03265249 | Pro00084620 | BRIDGE | February 15, 2018 | October 1, 2018 | October 1, 2018 | August 29, 2017 | February 1, 2018 | ||
36 | NCT02966834 | Recruiting | Dose Response Study of GSK2330672 for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
118 | All | 18 Years to 80 Years (Adult, Senior) | NCT02966834 | 201000 | January 11, 2017 | August 9, 2019 | August 9, 2019 | November 17, 2016 | April 10, 2018 |
|
||
37 | NCT01200082 | Recruiting | Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases |
|
Observational |
|
Other |
|
|
400 | All | 19 Years to 65 Years (Adult) | NCT01200082 | 487-10-EP | November 2011 | December 31, 2020 | December 31, 2020 | September 13, 2010 | September 11, 2017 |
|
||||
38 | NCT01931644 | Recruiting | Be the Bridge Between Researchers and a Cure (GVHD, ALS, Hepatitis B, Alzheimer's Disease, Leukemia, and More) |
|
Observational |
|
Industry |
|
|
20000 | All | 18 Years to 100 Years (Adult, Senior) | NCT01931644 | SAN-BB-01 | July 2013 | August 2020 | December 2040 | August 29, 2013 | April 18, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.